CABALETTA BIO INC (CABA)

US12674W1099 - Common Stock

14.7  -0.16 (-1.08%)

After market: 14.7 0 (0%)

CABALETTA BIO INC

NASDAQ:CABA (9/27/2023, 7:16:05 PM)

After market: 14.7 0 (0%)

14.7

-0.16 (-1.08%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-10 2023-08-10/bmo
Earnings (Next)11-08 2023-11-08/bmo
Ins Owners3%
Inst Owners91.54%
Market Cap585.13M
Shares39.80M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts83.33
IPO10-25 2019-10-25
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CABA Daily chart

Company Profile

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 77 full-time employees. The company went IPO on 2019-10-25. The firm is focused on the discovery and development of engineered T cell for the treatment of patients with autoimmune diseases. Its CABA platform encompasses two approaches: chimeric antigen receptor T cells for autoimmunity (CARTA) and chimeric autoantibody receptor T cells (CAART). Its product candidates include CABA-201, DSG3-CAART, DSG3/1-CAART, MuSK-CAART and PLA2R-CAART. Its lead product candidate, CABA-201, is designed to achieve transient depletion of all CD19-positive B cells following a single infusion, allowing for the elimination disease-causing B cells with subsequent repopulation by naive healthy B cells. Its lead product candidate for the CAART strategy, DSG3-CAART, is designed to enable specific cytotoxicity toward B cells autoreactive to DSG3. Its next PV product candidate, DSG3/1-CAART, is being designed to target DSG3 and/or DSG1 autoreactive B cell receptors on pathogenic B cells that cause mcPV.

Company Info

CABALETTA BIO INC

2929 Arch Street, Suite 600

PHILADELPHIA PENNSYLVANIA 19104

P: 12677593100.0

CEO: Steven Nichtberger

Employees: 77

Website: https://www.cabalettabio.com/

CABA News

News Image6 days ago - Seeking AlphaCabaletta Bio director purchases, sells shares in company (NASDAQ:CABA)

Cabaletta Bio (CABA) shares dropped ~4% as director Binder Gwendolyn sold off a significant number of shares after making a smaller purchase in the company.

News Image9 days ago - Cabaletta BioCabaletta Bio to Participate in Upcoming Investor Conferences in September
News Image9 days ago - Cabaletta BioCabaletta Bio to Participate in Upcoming Investor Conferences in September

PHILADELPHIA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...

News Imagea month ago - InvestorPlaceThe 7 Most Promising Momentum Stocks to Own Now

These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility.

News Imagea month ago - Cabaletta BioCabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
News Imagea month ago - Cabaletta BioCabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

PHILADELPHIA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...

CABA Twits

Here you can normally see the latest stock twits on CABA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example